Weight-gaining medications used by patients followed up at the bariatric and metabolic surgery service of a university hospital

Objective: To verify an association between weight and use of medications that lead to weight gain (MLGP) in a population of obese patients monitored in the Unified Health System. Methods: This is a retrospective descriptive sectional study with data from medical records of all patients. patients treated by the University Hospital Multiprofessional Service for obese patients who are candidates for bariatric surgery. The collection took place from January 2014 to March 2016. A weight-dependent variable, used in the body mass index (BMI) and degree of obesity and as independent variables of sex, age, education, income, number of diseases, number of drugs and number of MLGP. The association was calculated using the Ro Spearman correlation and the chi-square test. Results: 102 patients were studied, mostly women (87%), with a mean BMI of 45.9 kg / m2 (min 32.56 - maximum 70.98 kg / m2 SD = 6.43). The main comorbidities were systemic arterial hypertension (65.7%) and osteoarticular disorders (39.2%). The average number of drugs per patient was 4.3 and the most used class was for the renin-angiotensin system (67.3%). MLGP corresponds to 10.4% of the drugs used and 27.4% of the patients use them. MLGP patients used an average of 5.8 medications and the most prevalent classes were betablocking agents (60.6%), followed by medications used in diabetes (24.2%). Atenolol and a glibenclamide were the most used MLGP. The mean BMI of patients who used more than one MLGP was 51 kg / m2. Conclusion: There was no correlation between weight and the use of MLGP in this population. However, patients who used the MLGP combination had a higher BMI.